Posted by Michael Wonder on 19 May 2019
Gilead’s $21,000 drug is being blamed for a plateau in HIV prevention
17 May 2019 - AIDS activists, CEO O’Day square off at congressional hearing.
In 2012, Gilead Sciences’ Truvada became the first drug ever approved to prevent HIV, the virus that causes AIDS. It was a public health triumph that was spurred by years of government-funded research.
Seven years later, efforts to prevent HIV in the U.S. have stalled. Only a fraction of U.S. patients who could benefit from the treatment -- known as PrEP -- are getting it.
